IOVAIovance Biotherapeutics, Inc.
What is the market doing?
No clear lean: in an uptrend, but a crowded short (+21% of shares).
In an uptrend, above its rising 50- and 200-day averages. Overbought (RSI 74). Price is +200% vs its 200-day average.
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How IOVA is trading
Iovance Biotherapeutics, Inc. is +613% over the past year while the S&P 500 is +18%: 594 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +200%
vs 200-day average · a clear uptrend
- RSI (14)
- 74
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 1.2%
Below its 52-week high
Details›
- Last close2026-10-09
- $14.61
- 1 monthS&P 500 +2.7%
- +79%
- 1 yearS&P 500 +18%
- +613%
- 5 yearsS&P 500 +88%
- −33%
- vs 50-day average$9.10
- +61%
- 52-week high
- $14.79
- 52-week low
- $1.81
- Annualised volatility
- 103%
| Year | Return |
|---|---|
| 2026 (year to date) | +435% |
| 2025 | −63% |
| 2024 | −9.0% |
| 2023 | +27% |
| 2022 | −67% |
| 2021 | −59% |
| 2020 | +68% |
| 2019 | +213% |
| 2018 | +11% |
| 2017 | +15% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +5.4% |
| Feb | 10 | 6 of 10 | +18% |
| Mar | 10 | 1 of 10 | −8.4% |
| Apr | 10 | 3 of 10 | −2.9% |
| May | 10 | 4 of 10 | −7.6% |
| Jun | 10 | 5 of 10 | +14% |
| Jul | 11 | 9 of 11 | +6.4% |
| Aug | 11 | 5 of 11 | +8.2% |
| Sep | 11 | 4 of 11 | +1.2% |
| Oct | 11 | 4 of 11 | −3.4% |
| Nov | 10 | 7 of 10 | +6.5% |
| Dec | 10 | 6 of 10 | +5.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.